Skip to content

incidenCe and predictOrs of heaRt fAiLure After Acute coronarY Syndrome: CORALYS

incidenCe and predictOrs of heaRt fAiLure After Acute coronarY Syndrome: CORALYS

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04895176
Acronym
CORALYS
Enrollment
10000
Registered
2021-05-20
Start date
2021-06-01
Completion date
2021-06-30
Last updated
2021-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Heart Failure

Brief summary

Single-cohort retrospective study evaluating the incidence and prognostic markers of heart failure following acute coronary syndrome treated by percutaneous coronary intervention

Detailed description

Acute coronary syndrome (ACS) is the most common cause of heart failure (HF) world-wide. Primary percutaneous coronary intervention (PCI) has deeply improved short and long-term survival after ACS, but his impact on incidence of downstream heart failure still remains unclear and heart failure after ACS represents the major driver of late morbidity, mortality and healthcare cost. Many predictors and determinant of heart failure after MI have been evaluated, however, to date, the optimal combination of parameters to predict heart failure after MI needs to be defined and very little is known about the prognostic markers in unstable angina setting The aim of this retrospective study: * to show the incidence of heart failure after acute coronary artery syndrome, and the relation between the type of ACS and following incidence of HF. * to clarify which features could be routinely identified as prognostic markers. This study is a multi-center non-randomized, single-cohort retrospective study including consecutive patients with acute coronary syndrome treated by percutaneous coronary intervention between 2017 and 2019, without known previous heart failure (baseline EF \> 40% and no medical therapy with loop diuretics), with at least 12 months of follow-up. It is possible to anticipate that the main findings of the present study will fill fundamental knowledge gaps regarding incidence of heart failure following coronary events. Among this, the study could suggest specific clinical and epidemiological features related to the risk of development of HF, leading to a better medical treatment and reducing risk for further hospitalizations.

Interventions

None listed

Sponsors

University of Turin, Italy
CollaboratorOTHER
A.O.U. Città della Salute e della Scienza
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* • Informed consent * Age ≥ 18 years * Previous acute coronary syndrome with percutaneous coronary revascularization * Baseline EF \> 40% * At least 12 months of follow-up

Exclusion criteria

* • Significant valvular heart disease (greater than mild stenosis or moderate regurgitation) before ACS * Type 1, 3, 4, 5 pulmonary hypertension (14) before ACS * Constrictive pericarditis before ACS * Primary or infiltrative cardiomyopathies * Heart transplantation * Medical therapy with loop diuretics for heart failure before ACS * Previous hospitalizations for heart failure or clinical sign of heart failure detected outpatient before ACS

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Heart Failure after Acute Coronary Artery Syndrome12 monthTo show the incidence of heart failure after acute coronary artery syndrome.
Identify prognostic markers12 monthTo clarify which features could be routinely identified as prognostic markers in this setting

Secondary

MeasureTime frameDescription
The relation between the type of ACS and incidence of HF12 monththe relation between the type of ACS and following incidence of HF will be investigated

Countries

Italy

Contacts

Primary ContactFabrizio D'Ascenzo, MD
fabrizio.dascenzo@gmail.com0039 011 633 6023

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026